[HTML][HTML] A new look at novel cardiovascular risk biomarkers: the role of atherogenic lipoproteins and innovative antidiabetic therapies
J Vekic, A Zeljkovic, K Al Rasadi, M Cesur… - Metabolites, 2022 - mdpi.com
The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical
practice; indeed, despite optimal management and treatment, a considerable proportion of …
practice; indeed, despite optimal management and treatment, a considerable proportion of …
A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies
J Vekic, A Zeljkovic, K Al Rasadi, M Cesur… - …, 2022 - search.proquest.com
The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical
practice; indeed, despite optimal management and treatment, a considerable proportion of …
practice; indeed, despite optimal management and treatment, a considerable proportion of …
A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies.
J Vekic, A Zeljkovic, K Al Rasadi… - Metabolites (2218 …, 2022 - search.ebscohost.com
The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical
practice; indeed, despite optimal management and treatment, a considerable proportion of …
practice; indeed, despite optimal management and treatment, a considerable proportion of …
A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies
J Vekic, A Zeljkovic, K Al Rasadi, M Cesur… - 2022 - agris.fao.org
The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical
practice; indeed, despite optimal management and treatment, a considerable proportion of …
practice; indeed, despite optimal management and treatment, a considerable proportion of …
A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies
J Vekic, A Zeljkovic, K Al Rasadi, M Cesur… - …, 2022 - squ.elsevierpure.com
The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical
practice; indeed, despite optimal management and treatment, a considerable proportion of …
practice; indeed, despite optimal management and treatment, a considerable proportion of …
[PDF][PDF] A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies
J Vekic, A Zeljkovic, K Al Rasadi, M Cesur… - Clin. Lab, 2009 - researchgate.net
The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical
practice; indeed, despite optimal management and treatment, a considerable proportion of …
practice; indeed, despite optimal management and treatment, a considerable proportion of …
[PDF][PDF] A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies
J Vekic, A Zeljkovic, K Al Rasadi, M Cesur… - Clin. Lab, 2009 - iris.unipa.it
The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical
practice; indeed, despite optimal management and treatment, a considerable proportion of …
practice; indeed, despite optimal management and treatment, a considerable proportion of …
A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies.
J Vekic, A Zeljkovic, K Al Rasadi, M Cesur… - Metabolites, 2022 - europepmc.org
The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical
practice; indeed, despite optimal management and treatment, a considerable proportion of …
practice; indeed, despite optimal management and treatment, a considerable proportion of …
A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies
J Vekic, A Zeljkovic, K Al Rasadi, M Cesur… - …, 2022 - pubmed.ncbi.nlm.nih.gov
The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical
practice; indeed, despite optimal management and treatment, a considerable proportion of …
practice; indeed, despite optimal management and treatment, a considerable proportion of …
[HTML][HTML] A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies
J Vekic, A Zeljkovic, K Al Rasadi, M Cesur… - Metabolites, 2022 - ncbi.nlm.nih.gov
The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical
practice; indeed, despite optimal management and treatment, a considerable proportion of …
practice; indeed, despite optimal management and treatment, a considerable proportion of …